Author: electrocore_admin

ElectroCore, Inc. Celebrates Veterans and Active Members of the Military During National Military Appreciation Month

ROCKAWAY, N.J.–(BUSINESS WIRE)– National Military Appreciation Month commemorates and expresses gratitude for the sacrifices current and former members of the U.S. armed forces have made for our country’s freedom. electroCore, Inc., a commercial-stage bioelectronic medicine company, is dedicated to the advancement and accessibility of healthcare solutions for veterans and hopes this important commemorative month will keep the health and treatment of military personnel top of mind.

ElectroCore Supports Results of Lancet Paper Highlighting the Benefits of Vagus Nerve Stimulation for Stroke Patients

electroCore, Inc., a commercial-stage bioelectronic medicine company, commends the results of the VNS-REHAB study published in the April 24th edition of The Lancet which demonstrated how vagus nerve stimulation (VNS) during rehabilitation can significantly improve arm function after an ischemic stroke. Effective treatments hold particular interest because stroke is the second highest cause of death and the third leading cause of disability globally, with ischemic stroke as the most common type of stroke. The results of the VNS-REHAB study build general excitement for the medical and scientific community’s ongoing efforts to find new and safe ways to treat the immediate or long-term disabilities faced by stroke patients.

From COVID to Migraines, FDA Cleared Device Provides Non-Drug Safe Pain Relief

(NewsUSA) – Persistent migraines and cluster headaches disrupt the lives, careers, and families of many people who struggle to find relief from debilitating pain. Migraine is one of the world’s most common health conditions, affects roughly 39 million people in the United States, making it the sixth most prevalent illness in the world according to the Institute for Health Metrics and Evaluation’s Global Burden of Disease study. In addition, recent studies on symptoms of “long-haul” Covid-19 states that migraine is a common long-term effect of the illness